Seattle, WANCT06188689Now EnrollingIRB Ready

Calcium Release Deficiency Syndrome (CRDS) Clinical Trial in Seattle, WA

Access cutting-edge calcium release deficiency syndrome (crds) treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by Population Health Research Institute

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access calcium release deficiency syndrome (crds) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related calcium release deficiency syndrome (crds) treatment provided free

Apply for This Seattle Location

Check if you qualify for this calcium release deficiency syndrome (crds) clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Calcium Release Deficiency Syndrome (CRDS) Study in Seattle

Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.

Sponsor: Population Health Research Institute

Who Can Participate

Inclusion Criteria

• Presence of an RyR2 variant confirmed to be loss-of-function on in vitro testing

Exclusion Criteria

• Unable to provide informed consent Cohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases Inclusion criteria:
Satisfy a clinical phenotype consistent with the Expert Consensus Statement
Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic/pathogenic CASQ2 variants Exclusion criteria:
Unable to provide informed consent
Use of a QT prolonging medication, aside from flecainide, at the time of the burst pacing maneuvers Cohort 3: Survivors of Unexplained Cardiac Arrest (UCA) Inclusion criteria:
Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test
Undergone genetic testing that includes screening of RyR2\
Unable to provide informed consent
Use of a QT prolonging medication at the time of the burst pacing maneuvers
Among survivors of UCA that possess a rare RyR2 variant in the absence of a CPVT phenotype, in vitro functional testing will be performed in order to confirm it is not loss- or gain-of-function (and will be arranged through the laboratory of Dr. Wayne Chen at the University of Calgary). Cohort 4: SVT controls Inclusion criteria: • Undergoing an invasive electrophysiology study Exclusion criteria:
Ventricular cardiomyopathy
Ventricular pre-excitation
Long QT syndrome
Use of a QT prolonging medication at the time of the EP study
Use of a Class I or Class III anti-arrhythmic drug at the time of the EP study
Known obstructive coronary artery disease (existing coronary stenosis \>50%)
Unable to provide informed consent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT06188689) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Calcium Release Deficiency Syndrome (CRDS) Treatment Options in Seattle, WA

If you're searching for calcium release deficiency syndrome (crds) treatment options in Seattle, WA, this clinical trial (NCT06188689) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced calcium release deficiency syndrome (crds) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all calcium release deficiency syndrome (crds) clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Seattle, WA

See all ankylosing spondylitis clinical trials recruiting in Seattle — not just this study.

Browse Ankylosing Spondylitis Trials in Seattle

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA